Drug Patent Watch
DECEMBER 17, 2024
Embracing Digital Transformation The role of Big Data and Artificial Intelligence in healthcare is growing exponentially. Flexible manufacturing systems will be crucial in producing small batches of tailored therapies efficiently. What role does digitalization play in enhancing CDMO flexibility?
pharmaphorum
DECEMBER 8, 2022
The advent of biologic therapies in the 1970s along with the decoding of the human genome in 2003 heralded an explosion in pharmaceutical innovation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ACRP blog
APRIL 5, 2023
Through these collaborations, advanced technologies tied to AI and big data are being employed to develop personalized and targeted medicines, ultimately leading to more effective treatments for diseases like cancer and immune deficiencies,” Lyons notes.
The Pharma Data
JULY 12, 2021
The study findings could measurably change how researchers sift through big data to find meaningful information with significant benefit to patients, the pharmaceutical industry and the nation’s health care systems. have access to unlimited amounts of ‘big data’ and better tools than ever to analyze such data.
pharmaphorum
JULY 4, 2022
A very important question was raised by the webinar attendee of the diversity and inclusion of patients in clinical research, and Dr Hackett commented: “A lot of the work has been done in our Paediatric & Rare Disease network, as well as our Cell and Gene Therapy network, we are tackling the issue of diversity in data.
XTalks
MAY 9, 2024
First, the integration of AI, big data and high-performance computing has the potential to not only expedite the drug discovery process, but also could contribute to better understanding of diseases at the molecular level. Tahi Ahmadi: Two key areas where we anticipate breakthroughs are technological advancements and new modalities.
XTalks
AUGUST 2, 2023
Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. Onureg (azacitidine), a leukemia therapy, also saw large growth of 70 percent to $124 million in 2022, and the multiple sclerosis drug Zeposia (ozanimod) generated $250 million in 2022, an 87 percent increase.
Expert insights. Personalized for you.
90 
Let's personalize your content